Video
JPM Week 2024: Addressing the Latest Market Drivers and Trends for Biologics and Sterile Injectables
Summary: In a recent presentation during the 2024 JP Morgan Healthcare Conference, Catalent’s Group President of Biologics Dave McErlane addresses the latest market drivers for Biologics and Sterile Injectables.
View Now
Executive Summary
Put your AAV on the Fast-Track to the Clinic
In this article, Catalent's experts detail a scalable approach to fast-tracking AAVs with integrated solutions, from clonal cell-lines to market.
View Now
Video
UpTempo℠ AAV Platform Process Accelerates Time From Gene To Clinic
Catalent's UpTempo AAV platform process offers clients accelerated timelines for producing their clinical materials. The scalable, CGMP-ready platform process can significantly reduce the time from gene to clinic through a simplified supply chain.
View Now
Webinars
One-Stop Integrated Viral Vector Platform for Speed to Clinic
Catalent experts discuss UpTempo℠ AAV, a one-stop integrated viral vector platform for speed to clinic. Discover how implementing the right process, utilizing a clonal HEK293 cell line, and leveraging a range of off-the-shelf plasmids, along with qualified analytical methods, can support a robust supply chain for the development and manufacture of AAV vectors.
View Now
White Papers
Bridging the Gap Between Promise and Practicality: Cell and Gene Therapy Advancements, Challenges, and the Path to Commercial Success
In recent years, the field of gene therapy has witnessed remarkable achievements and advancements. These breakthroughs have brought us even closer to unleashing the full potential of gene therapies. Catalent gene therapy experts discuss all aspects of gene therapy commercialization in depth.
View Now
Webinars
Accelerating Your Gene Therapy to Patients: Not All Platforms Are Created Equal
In this fireside chat, George Buchman, Ph.D., Vice President, Pre-Clinical and Process Development, Catalent Cell & Gene Therapy and Thomas VanCott, Ph.D., Chief Scientific Officer, Combined Therapeutics, explore how a complete platform approach to fast-track AAVs can enhance quality and efficiency.
View Now
Webinars
Exploring a One-Stop Integrated Solution for AAV Vector Clinical Production
Learn how the right process, clonal HEK293 cell line, and range of off-the-shelf plasmids, along with qualified analytical methods supports a robust supply chain for the development and manufacture of AAV vectors, and the reduction of timelines to clinical evaluation.
View Now
Webinars
GMP Process for High-Quality iPSC Manufacturing and Development of Improved Differentiation Methodologies
In this webinar, experts will discuss the evolution of protocols associated with induced pluripotent stem cell generation and differentiation.
View Now
Executive Summary
Early Phase Support for Plasmid DNA Supply to Secure Future Manufacturing
Summary: One significant challenge in the manufacturing of cell and gene therapies is the production of high quality plasmid DNA (pDNA). pDNA is a critical raw material for advanced therapeutics including mRNA and viral vector-based cell and gene therapies and vaccines.
View Now
Article
White Papers
Advancing Towards a Universal Platform for iPSC-Based Therapies
Human induced pluripotent stem cells (iPSCs) enable availability of next-generation cell therapies for broader patient population at a faster turnaround time for a variety of disease areas. Two Catalent Cell & Gene Therapy experts discuss the use of iPSCs as starting materials for cellular therapies, including the concept behind a universal platform for iPSC-based therapies.
View Now